LNC Platform (siRNA/ASO delivery)

About Matinas Biopharma

Matinas BioPharma is focused on overcoming significant drug delivery challenges through its disruptive Lipid Nano-Crystal (LNC) platform, which enables oral, intracellular delivery of complex molecules. The company's most advanced program, MAT2203, aims to transform the treatment of invasive fungal infections by offering an oral, less toxic alternative to intravenous amphotericin B. With a robust IP portfolio, a scalable GMP manufacturing facility, and a pipeline extending into oncology and inflammation, Matinas is positioning its platform technology for broad therapeutic application and potential partnerships.

About Matinas Biopharma

Matinas BioPharma is focused on overcoming significant drug delivery challenges through its disruptive Lipid Nano-Crystal (LNC) platform, which enables oral, intracellular delivery of complex molecules. The company's most advanced program, MAT2203, aims to transform the treatment of invasive fungal infections by offering an oral, less toxic alternative to intravenous amphotericin B. With a robust IP portfolio, a scalable GMP manufacturing facility, and a pipeline extending into oncology and inflammation, Matinas is positioning its platform technology for broad therapeutic application and potential partnerships.

Therapeutic Areas